1. PlexurM: Addressable market of $158 million. Targets for Osteotech are 5% by the end of 2010 ($7.9 million) and 10% by the end of 2011 ($15.8 million). 2. MagniFuse (in spine alone): Addressable market of $850 million. Osteotech goals are 3.5% share by the end of 2010 ($29.75 million) and 7% share by the end of 2011 ($59.5 million). It was noted that the addressable market for interbody is much greater than spine alone, but that will come later in 2010, as additional procedure-specific versions of the product continue to be released. 3. FacetLinx: Addressable market given as a range of $40-$50 million, so let's call it $45 million. Targets for Osteotech are 7% by the end of 2010 ($3.15 million) and 15% by the end of 2011 ($6.75 million). And of course DuraTech, when approved, will make a significant contribution also. The number of distributors has been reduced from 50 to 31, but the total number of sales reps has increased from 200 to more than 725.